﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>5</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2015</Year>
        <Month>11</Month>
        <DAY>30</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Preventing Aggregation of Recombinant Interferon beta-1b in Solution by Additives: Approach to an Albumin-Free Formulation</ArticleTitle>
    <FirstPage>497</FirstPage>
    <LastPage>505</LastPage>
    <ELocationID EIdType="doi">10.15171/apb.2015.068</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Najmeh</FirstName>
        <LastName>Mahjoubi</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad Reza</FirstName>
        <LastName>Fazeli</LastName>
      </Author>
      <Author>
        <FirstName>Rassoul</FirstName>
        <LastName>Dinarvand</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad Reza</FirstName>
        <LastName>Khoshayand</LastName>
      </Author>
      <Author>
        <FirstName>Ahmad</FirstName>
        <LastName>Fazeli</LastName>
      </Author>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Taghavian</LastName>
      </Author>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Rastegar</LastName>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.15171/apb.2015.068</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2015</Year>
        <Month>01</Month>
        <Day>25</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2015</Year>
        <Month>07</Month>
        <Day>30</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: Aggregation suppressing additives have been used to stabilize proteins duringmanufacturing and storage. Interferonβ-1b is prone to aggregation because of being nonglycosylated.Aggregation behavior of albumin-free formulations of recombinant IFNβ-1bwas explored using additives such as n-dodecyl-β-D-maltoside, Tween 20, arginine,glycine, trehalose and sucrose at different pH.Methods: Fractional factorial design was applied to select major factors affectingaggregation in solutions. Box-Behnken technique was used to optimize the bestconcentration of additives and protein.Results: Quadratic model was the best fitted model for particle size, OD350 andOD280/OD260. The optimal conditions of 0.2% n-Dodecyl-β-D-maltoside, 70 mMarginine, 189 mM trehalose and protein concentration of 0.50 mg/ml at pH 4 were achieved.A potency value of 91% ± 5% was obtained for the optimized formulation.Conclusion: This study shows that the combination of n-Dodecyl-β-D-maltoside, arginineand trehalose would demonstrate a significant stabilizing and anti-aggregating effect on theliquid formulation of interferonβ-1b. It can not only reduce the manufacturing costs but willalso ease patient compliance.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">n-Dodecyl-β-D-maltoside</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Optimization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HSA-free formulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Aggregation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Box-Behnken experimental design</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>